Key Finding: Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a protein replacement therapy for Friedreich’s ataxia, with recent positive long-term data and initiation of a rolling BLA submission supporting accelerated approval potential, though the stock remains highly volatile amid safety concerns and insider activity.
Fact: Larimar Therapeutics, Inc. (NASDAQ: LRMR) is headquartered in Bala Cynwyd, Pennsylvania (Philadelphia area). It is a clinical-stage biotechnology company focused on treatments for complex rare diseases using a proprietary intracellular protein replacement therapy platform based on cell-penetrating peptides.
Fact: Lead candidate: nomlabofusp (formerly CTI-1601), a recombinant fusion protein designed to deliver human frataxin (FXN) to mitochondria in patients with Friedreich’s ataxia (FA), a rare, progressive, fatal genetic disease caused by FXN deficiency.
Interpretation: The focus on root-cause treatment via protein delivery positions Larimar in a high-unmet-need niche, potentially differentiating it from symptomatic therapies.
Fact: The legal entity traces its roots to Zafgen, Inc. (founded ~2005, originally focused on obesity/metabolic drugs). In 2020, Zafgen merged with Chondrial Therapeutics (which had developed the FA program), rebranded as Larimar Therapeutics, and shifted exclusively to rare disease therapies centered on FA.
Fact: Public listing under LRMR on NASDAQ followed the merger. The company has advanced nomlabofusp through clinical stages with multiple regulatory incentives.
Uncertainty/Limitation: Detailed pre-2020 operational history under Zafgen is less relevant to current strategy; exact merger financials and early trial data require SEC filings for full verification.
Fact (as of ~July 9-10, 2026 data): Shares trade on NASDAQ. Recent closing prices have fluctuated significantly (e.g., around $3.61 with intraday moves to $4.13+). Market capitalization approximately $375 million. 52-week range: $2.72 – $6.42.
| Metric | Value | Notes |
|---|---|---|
| Recent Close | ~$3.61 (+5.87% example day) | Volatile daily swings common in biotech |
| Market Cap | ~$375M | Small-cap biotech |
| 52-Week High | $6.42 | Reached earlier in period |
| 52-Week Low | $2.72 | Recent support level |
| YTD Performance | Slightly negative (~-5% to -9% range) | Dependent on exact start date |
| Analyst Consensus Target | ~$12.71 (highs to $25) | Significant upside implied but speculative |
Links for more information:
Interpretation: As a pre-revenue clinical biotech, LRMR exhibits classic high-beta behavior driven by clinical/regulatory catalysts rather than fundamentals. Recent volatility reflects both positive BLA progress and safety disclosures.
Uncertainty: Historical prices pre-2020 reflect Zafgen's different business; future performance heavily dependent on nomlabofusp approval timeline (uncertain beyond 2026 BLA initiation).
Interpretation: BLA progress is a major de-risking event, but safety concerns introduce regulatory and legal overhangs that could delay or impact approval.
Data Limitations & Assumptions: All information derived from publicly available web sources as of July 2026. Stock prices are real-time volatile and not guaranteed; historical data may include pre-merger Zafgen activity. Clinical timelines, regulatory outcomes, and financial results are subject to change. This is not investment advice. Consult official SEC filings, company press releases, and licensed advisors. No private or non-public data used.
Sources include company website (larimartx.com), Yahoo Finance, Nasdaq, StockTwits, and analyst notes via search aggregates.